Analysts at StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ – Get Rating) in a note issued to investors on Tuesday. The firm set a “hold” rating on the medical research company’s stock.
Separately, TheStreet cut Enzo Biochem from a “c-” rating to a “d+” rating in a research note on Tuesday, May 17th.
Shares of ENZ stock opened at $2.19 on Tuesday. The stock has a market cap of $106.70 million, a price-to-earnings ratio of -16.85 and a beta of 0.81. The stock has a 50-day moving average of $2.47 and a 200-day moving average of $2.95. The company has a current ratio of 2.52, a quick ratio of 1.92 and a debt-to-equity ratio of 0.07. Enzo Biochem has a 1-year low of $2.09 and a 1-year high of $4.15.
A number of large investors have recently made changes to their positions in the business. Fuller & Thaler Asset Management Inc. lifted its holdings in Enzo Biochem by 0.5% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 946,285 shares of the medical research company’s stock worth $3,038,000 after acquiring an additional 4,525 shares during the period. Bank of New York Mellon Corp lifted its holdings in Enzo Biochem by 6.3% during the first quarter. Bank of New York Mellon Corp now owns 90,158 shares of the medical research company’s stock worth $261,000 after acquiring an additional 5,328 shares during the period. Morgan Stanley lifted its holdings in Enzo Biochem by 66.9% during the second quarter. Morgan Stanley now owns 13,551 shares of the medical research company’s stock worth $43,000 after acquiring an additional 5,432 shares during the period. BlackRock Inc. lifted its holdings in Enzo Biochem by 0.5% during the first quarter. BlackRock Inc. now owns 1,540,591 shares of the medical research company’s stock worth $4,468,000 after acquiring an additional 7,420 shares during the period. Finally, Northern Trust Corp lifted its holdings in Enzo Biochem by 7.0% during the fourth quarter. Northern Trust Corp now owns 114,523 shares of the medical research company’s stock worth $367,000 after acquiring an additional 7,462 shares during the period. Institutional investors and hedge funds own 59.64% of the company’s stock.
About Enzo Biochem (Get Rating)
Enzo Biochem, Inc, an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.
- Get a free copy of the StockNews.com research report on Enzo Biochem (ENZ)
- Ride Out The Recession With These Dividend Kings
- MarketBeat: Week in Review 6/13 – 6/17
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.